Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.74 +1.8%	$1.59	$1.03 ▼ $2.41	$53.35M	-0.53	413,994 shs	122,957 shs
IMCC IM Cannabis	$2.36 +8.0%	$2.81	$1.29 ▼ $7.12	$12.12M	2.2	45,486 shs	45,040 shs
QNTM Quantum Biopharma	$18.08 +0.2%	$22.59	$2.70 ▼ $38.25	$52.58M	0.71	190,791 shs	76,613 shs
UNCY Unicycive Therapeutics	$4.20 -1.2%	$4.96	$2.83 ▼ $11.00	$74.18M	1.88	480,332 shs	409,439 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	0.00%	+2.96%	-4.40%	+6.10%	-17.92%
IMCC IM Cannabis	0.00%	-11.47%	-17.94%	+23.30%	-19.35%
QNTM Quantum Biopharma	0.00%	-19.47%	-24.13%	+56.54%	+1,807,999,900.00%
UNCY Unicycive Therapeutics	0.00%	-10.64%	-13.40%	-24.08%	+11.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	2.3083 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.0	0.6
IMCC IM Cannabis	0.4888 of 5 stars	0.0	5.0	0.0	0.0	1.5	0.0	0.0
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	2.6151 of 5 stars	3.7	2.0	0.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$4.50	158.62% Upside
IMCC IM Cannabis	0.00	N/A	N/A	N/A
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,328.57% Upside

Current Analyst Ratings Breakdown

Latest IMCC, QNTM, ATNM, and UNCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/18/2025	QNTM Quantum Biopharma	Singular Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
IMCC IM Cannabis	$39.44M	0.31	N/A	N/A	$0.56 per share	4.21
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$0.70 per share	N/A
UNCY Unicycive Therapeutics	$680K	109.08	N/A	N/A	$0.93 per share	4.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.31	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
IMCC IM Cannabis	-$7.72M	-$0.54	N/A	N/A	N/A	-4.19%	-59.80%	-5.15%	11/12/2025 (Estimated)
QNTM Quantum Biopharma	-$14.20M	-$14.02	N/A	N/A	N/A	N/A	-270.22%	-131.87%	11/10/2025 (Estimated)
UNCY Unicycive Therapeutics	-$36.73M	-$4.12	N/A	N/A	N/A	N/A	-243.13%	-119.46%	11/12/2025 (Estimated)

Latest IMCC, QNTM, ATNM, and UNCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	UNCY Unicycive Therapeutics	-$0.70	-$0.52	+$0.18	-$0.52	N/A	N/A
8/12/2025	Q2 2025	IMCC IM Cannabis	-$0.1367	-$0.0653	+$0.0714	-$0.07	$12.88 million	$9.21 million
8/6/2025	Q2 2025	QNTM Quantum Biopharma	-$0.17	-$3.23	-$3.06	-$3.23	$2.89 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
IMCC IM Cannabis	0.32	0.72	0.62
QNTM Quantum Biopharma	N/A	0.78	0.77
UNCY Unicycive Therapeutics	N/A	2.18	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
IMCC IM Cannabis	7.68%
QNTM Quantum Biopharma	1.24%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
IMCC IM Cannabis	5.91%
QNTM Quantum Biopharma	8.53%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
IMCC IM Cannabis	340	5.25 million	4.94 million	Not Optionable
QNTM Quantum Biopharma	N/A	2.91 million	2.66 million	N/A
UNCY Unicycive Therapeutics	9	17.66 million	15.77 million	Not Optionable

IMCC, QNTM, ATNM, and UNCY Headlines

Recent News About These Companies

UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

2 hours ago | globenewswire.com

UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. and Encourages Investors to Contact the Firm

August 23 at 9:18 AM | globenewswire.com

Wall Street Zen Downgrades Unicycive Therapeutics (NASDAQ:UNCY) to Sell

August 23 at 2:21 AM | americanbankingnews.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 14, 2025 in Unicycive Therapeutics, Inc. Lawsuit – UNCY

August 22 at 4:40 PM | globenewswire.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

August 22 at 10:45 AM | globenewswire.com

Kaplan Fox Alerts Investors of Unicycive Therapeutics, Inc. (UNCY) to a Securities Class Action Deadline on October 14, 2025

August 22 at 10:25 AM | theglobeandmail.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY

August 22 at 10:00 AM | prnewswire.com

Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY

August 22 at 8:45 AM | prnewswire.com

Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) - October 14, 2025 Deadline to Join – Contact The Gross Law Firm

August 21 at 3:38 PM | globenewswire.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

August 21 at 11:05 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 21 at 10:16 AM | globenewswire.com

Shareholders that lost money on Unicycive Therapeutics, Inc.(UNCY) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

August 21 at 8:45 AM | prnewswire.com

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.

August 21 at 7:05 AM | prnewswire.com

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately

August 20, 2025 | globenewswire.com

UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 20, 2025 | prnewswire.com

Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD

August 19, 2025 | msn.com

Unicycive Therapeutics, Inc.: Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

August 19, 2025 | finanznachrichten.de

Unicycive Posts 65% EPS Gain in Q2

August 19, 2025 | theglobeandmail.com

UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 18, 2025 | globenewswire.com

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. ...

August 18, 2025 | gurufocus.com

Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS

August 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC, QNTM, ATNM, and UNCY Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.74 +0.03 (+1.75%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.74 0.00 (-0.29%)

As of 08/22/2025 07:33 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

IM Cannabis NASDAQ:IMCC

$2.36 +0.18 (+8.03%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$2.35 -0.01 (-0.42%)

As of 08/22/2025 07:49 PM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

Quantum Biopharma NASDAQ:QNTM

$18.08 +0.03 (+0.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$18.74 +0.66 (+3.62%)

As of 08/22/2025 07:58 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Unicycive Therapeutics NASDAQ:UNCY

$4.20 -0.05 (-1.18%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.23 +0.03 (+0.62%)

As of 08/22/2025 07:54 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time